(NASDAQ: CRVO) Cervomed's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 44.08%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 42.53%.
Cervomed's earnings in 2025 is -$25,584,991.On average, 8 Wall Street analysts forecast CRVO's earnings for 2025 to be -$23,235,428, with the lowest CRVO earnings forecast at -$26,840,287, and the highest CRVO earnings forecast at -$13,407,190. On average, 8 Wall Street analysts forecast CRVO's earnings for 2026 to be -$18,554,477, with the lowest CRVO earnings forecast at -$26,205,551, and the highest CRVO earnings forecast at -$5,246,292.
In 2027, CRVO is forecast to generate -$12,174,728 in earnings, with the lowest earnings forecast at -$18,951,419 and the highest earnings forecast at -$3,303,221.